Guest guest Posted June 26, 2012 Report Share Posted June 26, 2012 Given the limitations in terms of efficacy, especially long term, and safety of the available unspecific symptom-relieving drugs, such as pure analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) [bjordal et al. 2004], there is a growing need for medications that offer acceptable short-term symptom control, but especially have a role in the medium- and long-term symptom management of the disease (symptom-modifying effect), with the possibility of delaying the progression of joint structure changes (structure-modifying effect), thereby modifying the evolution of the disease, and thus preventing clinically significant disease outcomes (disease-modifying effect). http://www.medscape.com/viewarticle/765735 A. Simpson, DC | Vice President, Medical DirectorThe CHP Group | Smart Solutions. Healthy Results. Like us on Facebook | Follow us on Twitter | Follow us on LinkedIn | www.chpgroup.com csimpson@... O | C6600 SW 105th Ave, Ste 115 | Beaverton, OR 97008 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.